Is IGF-1 LR3 safe?

The LR3 modification adds 13 amino acids to the N-terminus and substitutes arginine at position 3. This dramatically reduces binding to IGF-binding proteins (especially IGFBP-3), which normally sequester native IGF-1. The result is a much longer half-life (~20–30 hours vs 12–15 hours for native IGF-1) and higher free circulating activity. The FDA-approved native IGF-1 (Increlex) is used for Laron syndrome — LR3 is a research compound without approval.

No. HGH (growth hormone) is the upstream signal; IGF-1 LR3 is one of its downstream mediators. When you inject GH, the liver produces IGF-1. When you inject IGF-1 LR3, you bypass the GH step entirely and act directly at the tissue level. They have different receptor targets, different risk profiles, and different effects on blood glucose.

This is a legitimate concern. IGF-1 is a known mitogenic and anti-apoptotic signal — it promotes cell growth and survival. Epidemiological studies have associated higher natural IGF-1 levels with increased risk of colorectal, breast, and prostate cancers. Whether the modest, cycling use of IGF-1 LR3 meaningfully elevates this risk in healthy adults is unknown, but the theoretical concern is not dismissed by serious researchers. Anyone with a personal or family history of these cancers should avoid IGF-1 supplementation.

CJC-1295 and Ipamorelin stimulate the pituitary to release GH, which then causes the liver to produce IGF-1. Adding exogenous IGF-1 LR3 bypasses this step and acts directly on tissues. Some users add it to extend and amplify the anabolic signaling cascade. However, this multi-compound approach creates compounding risks and is well beyond what any clinical evidence supports.